Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas. Learn more at www.kymeratx.com
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $197M
Founded date: 2016
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.03.2020 | Series C | $102M | - |
| 13.11.2018 | Series B | $65M | - |
| 30.10.2017 | Series A | $30M | - |
Mentions in press and media 26
| Date | Title | Description | Source |
| 08.03.2024 | Kymera Therapeutics Presents Preclinical Data for STAT6 and ... | - | globenewsw... |
| 07.12.2023 | Kymera Therapeutics Announces First Patient Dosed in Phase 2... | - | globenewsw... |
| 27.10.2023 | Kymera Therapeutics Announces First Patient Dosed in Phase 2... | - | globenewsw... |
| 27.10.2023 | Kymera Therapeutics Announces First Patient Dosed in Phase 2... | The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected lat... | einpresswi... |
| 09.06.2023 | Kymera Therapeutics Presents Data Demonstrating Superior Eff... | A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compare... | einpresswi... |
| 22.05.2023 | Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating O... | /EIN News/ -- WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ... | einpresswi... |
| 16.12.2021 | A-Alpha Bio Partners with Kymera Therapeutics to Discover No... | “Kymera and A-Alpha share a commitment to innovation and to expanding the potential of targeted prot... | prweb.com/... |
| 12.03.2020 | Kymera Therapeutics Announces $102 Million Series C Financin... | Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent ... | citybizlis... |
| 12.03.2020 | Kymera Therapeutics Raises $102M in Series C Financing | Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company pioneering targeted protein... | finsmes.co... |
| 12.03.2020 | Kymera Therapeutics Scoops Up $102M Series C | CAMBRIDGE, MA, Kymera Therapeutic today announced the closing of a $102 million Series C financing... | vcnewsdail... |
Show more